Objective Treatment of acute myeloid leukemia (AML) remains a challenge. It is urgent to
understand the microenvironment to improve therapy and prognosis. Methods …

Introduction Acute myeloid leukemia (AML) is the most common and deadly type of leukemia
affecting adults. It is typically managed with rounds of non-targeted chemotherapy followed …

Simple Summary Acute myeloid leukemia (AML) is a cancer of blood and bone marrow that
causes rapid production of abnormal red and white blood cells. Once established, the …

Myeloid cells, including antigen-presenting cells (APCs) and myeloid-derived suppressor
cells (MDSCs) play opposing roles to orchestrate innate and adaptive immune responses …

Galectin-9 (Gal-9) is a vital member of the galectin family, functioning as a multi-subtype
galactose lectin with diverse biological roles. Recent research has revealed that Gal-9's …

Simple Summary The disaccharide lactose is a common excipient in pharmaceutical
products. In addition, the two anomers α-and β-lactose can exert immuno-modulatory effects …

Aplastic anemia (AA) is a lethal hematological disorder; however, its pathogenesis is not
fully understood. Although immunosuppressive therapy (IST) is a major treatment option for …

Acute B lymphoblastic leukemia (B-ALL) relapse contributes predominantly to the mortality
after allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, the …

Introduction The introduction of target molecules and immunological therapies is changing
the treatment landscape of acute myeloid leukemia (AML). Areas covered We recapitulate …

Immunotherapy remains underexploited in acute myeloid leukemia (AML) compared to other
hematological malignancies. Currently, gemtuzumab ozogamicin is the only therapeutic …